Prediction of the response of colorectal cancer to systemic therapy
- 1 February 2002
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 3 (2), 75-82
- https://doi.org/10.1016/s1470-2045(02)00648-4
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Science, medicine, and the future: DNA microarrays in medical practiceBMJ, 2001
- Vascular endothelial growth factor (VEGF) – a valuable serum tumour marker in patients with colorectal cancer?European Journal of Surgical Oncology, 2001
- Quantitative Gene Expression Analysis in Microdissected Archival Formalin-Fixed and Paraffin-Embedded Tumor TissueThe American Journal of Pathology, 2001
- Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinomaEuropean Journal Of Cancer, 2000
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancerBritish Journal of Surgery, 2000
- Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal CancerNew England Journal of Medicine, 2000
- bcl‐2 protein expression is associated with better prognosis in colorectal cancerHistopathology, 1999
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJCI Insight, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998